Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector. The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate…
GenomeFrontier Theraputics AU has partnered with BioCina for a project to develop products for gene therapy cancer treatments.
Pharmaceutical and vaccine manufacturer BioCina is industry partner in an ambitious research project that aims to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis. BioCina, the health Security Systems Australia (HSSA) division of defence innovation group DMTC, and academics led by Griffith University, including the Australian Rickettsial Reference Laboratory…
Biotechnology company BioCina is expanding the capabilities of its Australian biologics facility (pictured), broadening its capabilities to manufacture mRNA-based vaccines and therapies. The factory, formerly owned by vaccines manufacturer Pfizer, is to employ a range of technologies from associated companies Cytiva and others associated with American medical group of companies Danaher, as well as collaborater…
Adelaide pharmaceutical group BioCina has announced the final transfer to it of ownership of the microbial-based pharmaceutical manufacturing facility formally operated by Hospira Adelaide, an affiliate of Pfizer Inc. The former-Pfizer site in Adelaide will now be operated by the company as a contract development and biologics manufacturing organization (CDMO) specialising in process development and…
By Peter Roberts Adelaide pharmaceutical group BioCina has joined the race to manufacture mRNA vaccines in Australia such as those made by Pfizer and Moderna which have proved effective in preventing infection from Covid-19. The Adelaide company, backed by the University of Adelaide, is one of a number of groups who have responded to a…
Private investment firm, Bridgewest Group has expanded its pharmaceuticals portfolio, announcing the purchase of the sterile injectable manufacturing facility of Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. The cGMP manufacturing facility, located in Bentley, Perth is a diverse sterile injectable manufacturing facility, approved to supply drug products in over 90 countries with approvals…
By Peter Roberts It seems a long time ago that Australia was in the grip of the Covid-19 pandemic and novel mRNA technologies were hot news. Though the technology had been around for decades it was the pandemic which saw the first major vaccines made using the genetic technology approved for public use in 2020,…
CSIRO has opened a new $23.1 million national laboratory in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and Therapeutics Lab will turn vaccine and drug candidates into products that can be manufactured in quantity for clinical trials. According to a statement from CSIRO,…
A second Australian-developed and manufactured Covid-19 vaccine has surfaced with the University of Adelaide commencing human trials of its new vaccine that targets the highly-transmissible Omicron variant of the disease. Manufactured by Adelaide company BioCina, the university’s DNA-based vaccine is being trialled at Royal Adelaide Hospital in partnership with PARC Clinical Services and SA Pathology.…
